Core Viewpoint - The company, Aorite Pharmaceutical Co., Ltd., has announced an adjustment to the maximum repurchase price of its shares from RMB 24.71 per share to RMB 35.00 per share, while keeping other aspects of the repurchase plan unchanged [2][9]. Group 1: Repurchase Plan Overview - The company approved a share repurchase plan on January 21, 2025, with a total fund amount between RMB 60 million and RMB 120 million, and an initial maximum repurchase price of RMB 25.00 per share [4]. - The maximum repurchase price was adjusted to RMB 24.71 per share due to the company's 2024 annual equity distribution, effective from June 20, 2025 [4]. Group 2: Progress of Share Repurchase - As of the announcement date, the company has repurchased a total of 2,627,238 shares, representing 0.65% of the total share capital, with a total expenditure of RMB 55,124,396.68 [5]. Group 3: Adjustment Details - The adjustment of the repurchase price limit is based on the recent stock price performance, which has consistently exceeded the previous limit, reflecting the company's confidence in its future development [6]. - The new maximum repurchase price is below 150% of the average stock price over the last 30 trading days prior to the adjustment [6]. Group 4: Impact of the Adjustment - The adjustment complies with relevant regulations and is expected to facilitate the smooth implementation of the repurchase plan without adversely affecting the company's operations, financial status, or future development [7]. - The adjustment will not change the company's control or its listing status, ensuring that the share distribution remains compliant with listing requirements [7].

Summary of Key Points Core Viewpoint - On January 12, several companies disclosed their shareholding changes, with notable increases in shareholdings from 恒实科技 and 奥锐特, while 16 A-share listed companies announced share reductions [1][2]. Group 1: Shareholding Increases - 恒实科技's controlling shareholder, 新基集团, plans to increase its stake by 1.5% to 3% [2]. - 奥锐特 intends to adjust its share repurchase price ceiling to no more than 35 yuan per share [2]. Group 2: Shareholding Reductions - 立中集团's five executives plan to reduce their holdings by no more than 0.0642% [2]. - 钧达股份's second largest shareholder, 控股股东锦迪科技, intends to reduce its stake by no more than 3% [2]. - 南兴股份's controlling shareholder, 南兴投资, has reduced its holdings by a total of 366,900 shares as of January 12 [2]. - 中国核建's second largest shareholder reduced its holdings by 7,866,600 shares from January 7 to 9, bringing its stake down to 10% [2]. - 天银机电's largest shareholder, 澜海瑞兴, reduced its holdings by 1,245,300 shares on January 12 [2]. - 信维通信's actual controller and chairman, 彭浩, plans to reduce his stake by no more than 1% [2]. - 中电港's fourth largest shareholder recently reduced its holdings by 7,596,900 shares, bringing its stake below 5% [2]. - 佰维存储's second largest shareholder, 国家集成电路基金二期, plans to reduce its stake by no more than 2% [2]. - 青木科技's largest and third largest shareholders recently reduced their holdings by a total of 1,937,400 shares [2]. - 长芯博创's shareholders plan to reduce their holdings by no more than 2.55% [2]. - 趣睡科技's shareholders plan to reduce their holdings by no more than 2.6% [2]. - 卓越新能's controlling shareholder, 龙岩卓越投资, plans to reduce its stake by no more than 3% [2].

Group 1: Company Buybacks - Hengshi Technology's controlling shareholder, New Base Group, plans to increase its stake by 1.5%-3% [1][2] - Aorite intends to adjust the maximum repurchase price of its shares to no more than 35 yuan per share [2] Group 2: Company Sell-offs - Lichong Group's five executives plan to reduce their holdings by no more than 0.0642% of the company's shares [2] - Junda Co., the second-largest shareholder, intends to reduce its stake by no more than 3% [2] - Nanxing Co. has reduced its holdings by a total of 3.669 million shares as of January 12 [2] - China Nuclear Engineering's second-largest shareholder reduced its holdings by 7.8666 million shares from January 7 to 9, lowering its stake to 10% [2] - Tianyin Machinery's largest shareholder, Lanhai Ruixing, reduced its holdings by 1.2453 million shares on January 12 [2] - XW Communication's actual controller and chairman, Peng Hao, plans to reduce his stake by no more than 1% [2] - Aerospace Development's controlling and fourth-largest shareholders reduced their holdings during periods of significant stock price fluctuations [2] - Tianfu Communication's senior management has completed a reduction of 80,000 shares [2] - Zhongdian Port's fourth-largest shareholder recently reduced its holdings by 7.5969 million shares, bringing its stake below 5% [2] - Baiwei Storage's 20th largest shareholder, the National Integrated Circuit Fund Phase II, plans to reduce its stake by no more than 2% [2] - Qingmu Technology's largest and third-largest shareholders have recently reduced their holdings by a total of 1.9374 million shares [2] - Changxin Bochuang's shareholders plan to reduce their holdings by no more than 2.55% [2] - Qusleep Technology's shareholders plan to reduce their holdings by no more than 2.6% [2] - Zhuoyue New Energy's controlling shareholder, Longyan Zhuoyue Investment, plans to reduce its stake by no more than 3% [2]

Group 1 - The company, Aorite, announced an adjustment to its share repurchase price limit from a maximum of RMB 24.71 per share to a maximum of RMB 35.00 per share, while keeping other details of the repurchase plan unchanged [2]

证券代码：605116 证券简称：奥锐特 公告编号：2026-003 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于调整回购价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 奥锐特药业股份有限公司（以下简称"公司"）于 2026 年 1 月 12 日召开 的第三届董事会第十八次会议，审议通过了《关于调整回购股份价格上限的议 案》，公司拟将回购股份价格上限由不超过人民币 24.71 元/股调整为不超过人民 币 35.00 元/股，回购方案的其他内容不变。 本次调整回购价格上限事项无需提交公司股东会审议。 一、回购股份的基本情况 2025 年 1 月 21 日，公司召开第三届董事会第十二次会议，会议以 9 票同意、 0 票反对、0 票弃权审议通过了《关于以集中竞价交易方式回购公司股份方案的 议案》，同意公司以集中竞价交易方式回购公司股份，回购的股份全部用于转换 公司可转债。本次回购股份的资金总额为不低于人民币 6,000 万元（含），不高 于人民币 12,000 万元（含）， ...

Group 1 - The company, Aorite (605116.SH), announced a plan to adjust the maximum repurchase price of its shares from RMB 24.71 per share to RMB 35.00 per share [1]

Company Performance - The stock price of Aorite reached a historical high, increasing by 8.17% to 30.58 yuan, with a trading volume of 16.094 million shares and a transaction value of 470 million yuan, resulting in a turnover rate of 3.96% [2] - For the first three quarters, the company achieved an operating income of 1.237 billion yuan, representing a year-on-year growth of 13.67%, and a net profit of 354 million yuan, reflecting a year-on-year increase of 24.58% [2] - The basic earnings per share were reported at 0.8700 yuan, with a weighted average return on equity of 14.37% [2] Industry Overview - The pharmaceutical and biotechnology industry, to which Aorite belongs, experienced an overall increase of 1.62%, with 413 stocks rising and 11 stocks, including Weikang Pharmaceutical and Dian Diagnostics, hitting the daily limit [2] - Conversely, 76 stocks in the industry saw declines, with the largest drops recorded by Meihua Medical, Aipeng Medical, and *ST Changyao, with declines of 10.52%, 8.26%, and 8.05% respectively [2]

Core Viewpoint - The innovative drug sector has experienced a strong rally since the beginning of 2026, driven by favorable policies, improving fundamentals, and a recovering capital market [1][4]. Group 1: Market Performance - The innovative drug concept sector in A-shares has seen a continuous rise, with multiple stocks, including Hainan Haiyao and Beibete-U, reaching their daily limit [1]. - Since the start of 2026, the innovative drug sector has recorded four consecutive days of gains, with over ten stocks rising more than 20% in four trading days, and Beibete-U's stock price has increased by nearly 70% [1][2]. Group 2: Policy and Regulatory Environment - The National Medical Products Administration (NMPA) has optimized the review and approval process for urgently needed foreign drugs, encouraging simultaneous global research and application in China [3]. - In 2025, China approved 76 innovative drugs for market entry, surpassing the 48 approved in 2024, marking a historical high [3]. Group 3: Industry Drivers - The recent rally in the innovative drug sector is attributed to several factors, including the implementation of new national medical insurance drug lists, which support the sales and market promotion of innovative drugs [4]. - The sector is also benefiting from advancements in cutting-edge fields such as ADC and small nucleic acids, attracting capital interest [4]. Group 4: Investment Focus - The investment focus for 2026 is shifting towards overseas expansion and emerging technologies, with an emphasis on business development (BD) as a long-term trend for Chinese innovative drugs [5]. - Companies with rapid milestone achievements in BD are expected to attract more market attention and investment opportunities [5].

每经AI快讯，1月8日，创新药概念持续走强，海南海药、奥锐特、必贝特-U涨停，苑东生物、泰恩 康、汇宇制药-W、奥赛康、上海谊众等跟涨。 （文章来源：每日经济新闻） ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 12 月 31 日，累计已有面值 9,000 元"奥 锐转债"转为公司 A 股普通股，累计转股股数为 353 股，占"奥锐转债"转股 前公司已发行普通股股份总额的 0.0001%。 未转股可转债情况：截至 2025 年 12 月 31 日，尚未转股的"奥锐转债" 面值为人民币 812,111,000 元，占"奥锐转债"发行总量的比例为 99.9989%。 证券代码：605116 证券简称：奥锐特 公告编号：2026-002 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于可转债转股结果暨股份变动公告 本季度转股情况："奥锐转债"自 2025 年 2 月 5 日起可转换为公司股票， 2025 年 10 月 1 日至 2025 年 12 月 31 日期间共有面值 1,000 元"奥锐转债"转 为公司 A 股普通股，转股后的股份数为 40 股。 一、可转债发行上市概况 （一）可转债发行情况 经中国证券监督管理委员 ...